Plain-English translation of NCT07528105 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing an experimental therapy called allogeneic CD7-targeted CAR-T cell therapy (RD13-02) in people with early-stage type 1 diabetes. The treatment uses specially engineered immune cells designed to reduce the autoimmune attack that destroys your pancreas's insulin-producing cells. Researchers want to see if this medication is safe and whether it can help preserve your remaining pancreatic function and reduce your dependence on insulin.
Type 1 diabetes happens when your immune system mistakenly attacks the cells in your pancreas that make insulin. Insulin injections keep you alive, but they don't stop the underlying immune attack. This trial exists to explore whether this new treatment can actually calm that immune system attack and preserve the pancreatic cells you still have left.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive one infusion of the experimental cell therapy and then attend regular clinic visits and blood tests to monitor your safety, blood sugar control, insulin needs, and how your immune system responds. The study will track your C-peptide levels (a measure of remaining pancreatic function), autoimmune markers, and any side effects. The exact duration and frequency of visits will be explained by the research team, but you should expect ongoing monitoring to understand how the treatment affects your diabetes over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China